USANew treatments and approvals
Accelerated approval for tividenofusp alfa for nervous system features of Hunter syndrome
A decision by a medicines regulator (FDA, European Commission, etc.). The regulator has reviewed the clinical studies behind the drug. For accelerated or conditional approvals, the lasting benefit is still being confirmed.
Through the accelerated pathway, the FDA has approved tividenofusp alfa for children with Hunter syndrome (MPS II). The drug is meant to treat the nervous system symptoms of the disease. It is used in children who have not developed advanced neurological damage. The child must weigh at least 5 kg. The drug is an enzyme therapy. It was designed to cross the blood-brain barrier. The approval is based on a decrease in heparan sulfate levels in the cerebrospinal fluid. Confirmatory study results are needed for full approval.
What does it mean for patients and families?
This is the first approved treatment targeting brain involvement in Hunter syndrome. Confirmation of its clinical benefit is ongoing. Access in Türkiye depends on TİTCK (Turkish Medicines and Medical Devices Agency) and SGK (Social Security Institution) processes.
Source
FDA: FDA Approves Drug to Treat Neurologic Manifestations of Hunter Syndrome
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Hunter syndrome (MPS II)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.